Lifeist Wellness Inc. (LFST.V)
| Previous Close | 0.1000 |
| Open | 0.0500 |
| Bid | 0.0900 x N/A |
| Ask | 0.1000 x N/A |
| Day's Range | 0.0500 - 0.1000 |
| 52 Week Range | 0.0500 - 0.9000 |
| Volume | |
| Avg. Volume | 34,381 |
| Market Cap | 2.97M |
| Beta (5Y Monthly) | 0.76 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Lifeist Announces TSXV Approval of Common Share Consolidation
TORONTO, May 10, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, today announced that, further to its news release dated April 30, 2024, the TSX Venture Exchange (the "Exchange") has approved the consolidation of the Company’s issued and outstanding common shares on the basis of one (1
- GlobeNewswire
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
Mikra partners with global leader in NutraBiosciences® to release CELLF 2.0 featuring improved flavor and consistency thanks to Virun’s patented technology TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, is pleased to announce that its U.S. biosciences subsidiary Mikra
- GlobeNewswire
Mikra Announces Joint Product with Jose Bautista
Mikra Completes Formulation of its First Joint Product with MLB Legend Jose BautistaTORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, is pleased to announce that its U.S. biosciences subsidiary Mikra Cellular Sciences Inc. ("Mikra") has completed formulation of its first
